OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
BRAIN Biotech AG OCF Yield % Related Terms
BRAIN Biotech AG OCF Yield % Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BRAIN Biotech AG's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG OCF Yield % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's OCF Yield % distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a OCF Yield % of -9.23 as of Jul. 02, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #1494 out of 1605 companies in the Chemicals industry, placing it in the top 93.1%.
Is BRAIN Biotech AG's OCF Yield % too high?
BRAIN Biotech AG's current OCF Yield % is -9.23. Based on the distribution chart, BRAIN Biotech AG ranks #1494 out of 1605 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BRAIN Biotech AG has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's OCF Yield % compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #1494 out of 1605 companies for OCF Yield %. This places BRAIN Biotech AG in the lower half of its industry. The industry median OCF Yield % is 4.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Chemicals company?
The median OCF Yield % among Chemicals companies is 4.49, based on 1,605 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median OCF Yield % is 4.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current OCF Yield % is -9.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.56, compared to a current price of €2.86 — trading 11.7% above its estimated fair value. The current OCF Yield % is -9.23. BRAIN Biotech AG's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current OCF Yield % is -9.23 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.86 is trading 11.7% above its estimated GF Value™ of €2.56.
GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.
Key valuation signals for HAM:BNN:
OCF Yield %: -9.23
GF Value™: €2.56 vs. price of €2.86 (11.7% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score
Get the complete analysis for HAM:BNN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
